# US 2021/0171579 A1 · Inhibitor using plant cyclopeptide as effective component for lipid metabolic abnormalities in cancer cells and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171579 A1
- Document ID: US20210171579A1
- Status: Published application
- Kind: A1
- Application number: 16/769,872
- Filed: 2018-05-14
- Published: 2021-06-10
- Earliest claimed: 2017-12-05
- Assignees: China Pharmaceutical University
- Applicants: China Pharmaceutical University
- Inventors: Ninghua TAN; Yurong WANG; Lihua SONG
- Web page: https://patentgrep.com/patent/US20210171579A1

## CPC

- C07K 9/006: {the peptide sequence being part of a ring structure}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61P 35/00: Antineoplastic agents
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure discloses an inhibitor for abnormal lipid metabolism of tumor cells with a plant cyclopeptide as an effective component, and discloses application of the inhibitor to preparation of drugs for inhibiting abnormal lipid metabolism of the tumor cells, which specifically can be applied to preparation of drugs for treating and preventing abnormal lipid metabolism related cancers including liver cancer, colon cancer, rectal cancer and prostatic cancer. The inhibitor for abnormal lipid metabolism of the cells of the present disclosure can effectively inhibit abnormal lipid metabolism of the tumor cells. Its effective component, the plant cyclopeptide, is wide in source and mature in extraction technology. The inhibitor has diversified dosage forms and medication ways and has a wide clinical application prospect.

## Claims

### Claim 1

An inhibitor for abnormal lipid metabolism of tumor cells, wherein an effective component of the inhibitor is a plant cyclopeptide.

### Claim 2 (depends on 1)

The inhibitor according to claim 1, wherein an effective component of the inhibitor is a rubiaceae-type cyclopeptide.

### Claim 3 (depends on 2)

The inhibitor according to claim 2, wherein an effective component of the inhibitor is a rubiaceae-type cyclopeptide RA-V or RA-XII shown in the following structural formulas.

### Claim 4 (depends on 1)

Application of the inhibitor according to claim 1 to preparation of drugs for treating and preventing diseases capable of benefiting from abnormal lipid metabolism of cells.

### Claim 5 (depends on 1)

Application of the inhibitor according to claim 1 to preparation of drugs for targeted inhibition of abnormal lipid metabolism of tumors.

### Claim 6 (depends on 5)

The application according to claim 5, wherein the tumors comprise liver cancer, colon cancer, rectal cancer, lung cancer, breast cancer and prostatic cancer.

### Claim 7 (depends on 5)

The application according to claim 5, wherein the drugs inhibit abnormal proliferation of tumor cells by inhibiting abnormal lipid metabolism of the tumor cells.
